Recent Updates
Recently added Catalysts

NNC6989-0001 A

Phase 1

Overweight | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Feb 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment96
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07437079A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityPHASE1 RECRUITING 96 — — Feb 24, 2026Jan 21, 2027Feb 27, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of treatment emergent adverse events (TEAE) - Part A
From time of dosing on Day1 until completion of the end of study visit (Day 7)

Measure in number of events.

Number of treatment emergent adverse events (TEAE) - Part B
From time of dosing on Day 1 until completion of the end of study visit (Day 14)

Measured in number of events

Secondary Endpoints
AUC; the area under the NNC6989-0001 plasma concentration-time curve - Part A
From pre-dose on Day 1 until completion of the end of study visit (Day 7)
Cmax; the maximum plasma concentration of NNC6989-0001 - Part A
From pre-dose on Day 1 until completion of the end of study visit (Day 7)
AUC; the area under the NNC6989-0001 plasma concentration-time curve - Part B
From pre-dose on Day 1 until completion of the end of study visit (Day 14)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NNC6989-0001EXPERIMENTALParticipants receive the investigational drug NNC6989-0001
PlaceboPLACEBO_COMPARATORParticipants receive placebo matched in appearance to the active drug.
Interventions
NameTypeDescription
NNC6989-0001 ADRUGParticipants assigned to the active intervention receive NNC6989-0001 A
Placebo (NNC6989-0001 A)DRUGParticipants assigned to the placebo, receive placebo matched in appearance to the active drug.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg/m\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg/m\^2 for Part B (MAD...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07437079primaryCompletionDate: changed
LOWMay 24, 2026NCT07437079studyFirstPostDate: changed